The Shift From 'Less Bad' to Genuinely Well
A recent piece in Psychiatric Times (April 2026) highlights a growing consensus among clinicians: when it comes to treatment-resistant depression (TRD), the goal shouldn't be settling for partial improvement. Leading psychiatrists are now pushing for aggressive, remission-focused care — a meaningful departure from the historically cautious approach of simply reducing symptom burden while managing side effect tolerance.
Treatment-resistant depression is typically defined as major depressive disorder that fails to respond adequately to at least two antidepressant trials of adequate dose and duration. It affects an estimated 30% of people diagnosed with major depression, and for many of those patients, the clinical journey is long, demoralizing, and marked by accumulating side effects from medications that never quite work. The Psychiatric Times discussion centers on the argument that this population deserves more than incremental relief — they deserve clinical strategies actively aimed at full remission.
The approaches discussed span several categories: optimization of existing pharmacotherapy, augmentation strategies, psychotherapy integration, neuromodulation (such as TMS and ECT), and — notably — interventional psychiatry options including ketamine and esketamine. What ties these approaches together in the current clinical conversation is a shared insistence on individualized treatment planning that weighs not just symptom response, but patient-defined quality of life, functional recovery, and long-term sustainability.
Where Low-Dose Ketamine Fits in This Picture
For readers exploring ketamine as a treatment option, this evolving clinical perspective is directly relevant. Ketamine — particularly in low-dose, sublingual or intranasal formulations used in outpatient settings — has emerged as a meaningful tool in the TRD management toolkit precisely because it operates through a fundamentally different mechanism than conventional antidepressants. Rather than acting on serotonin or norepinephrine reuptake, ketamine modulates glutamate signaling through NMDA receptor antagonism, producing rapid antidepressant effects in many patients who have not responded to standard treatments.
The push toward remission-focused care matters here because it changes how clinicians should be thinking about ketamine's role — not just as a crisis intervention or a last resort, but as part of a structured, longer-term strategy. If the clinical bar is genuine remission rather than symptom reduction, then decisions about dosing frequency, maintenance intervals, and combination with therapy or other medications become more consequential. A single acute series of infusions that produces temporary relief but no durable remission may no longer be considered an adequate outcome by these newer standards.
This is particularly relevant to low-dose ketamine protocols, where the slower titration and lower peak plasma concentrations are designed to prioritize tolerability and outpatient safety. The trade-off historically has been a potentially more gradual or modest antidepressant response compared to higher-dose IV infusion protocols. The remission-focused framework now being articulated by clinicians raises an important question for practitioners and patients alike: is the current protocol actually moving toward remission, or managing symptoms at a tolerable baseline?
Key Takeaway
The clinical shift toward remission as the target — not just symptom relief — means patients and providers should be having more explicit conversations about what success actually looks like. If you're in a low-dose ketamine protocol and experiencing partial improvement, it may be worth discussing with your prescriber whether your current approach is optimized for deeper, more durable response, or whether adjunct strategies (therapy, augmentation, dosing adjustments) could move the needle further.
What This Means for Dosing, Maintenance, and Monitoring
The remission-oriented framework has practical implications across several dimensions of ketamine care:
Dosing and titration: Remission, not just response, may require individualized dose optimization over time. Low-dose protocols that start conservatively for safety reasons should still include structured reassessment — if a patient has stabilized at a dose that produces partial improvement after several weeks, clinicians should actively evaluate whether titration upward (within safe limits) might yield fuller response. Staying at a subtherapeutic dose indefinitely because it's 'working a little' is exactly the kind of 'less bad' outcome this clinical shift is pushing against.
Maintenance intervals: TRD by definition involves recurrence risk. The Psychiatric Times framework emphasizes long-term sustainability, which for ketamine patients means maintenance dosing is not a sign of treatment failure — it's a feature of responsible long-term management. Patients should understand that maintenance ketamine use is an accepted and evidence-supported component of durable remission, not a crutch or a red flag.
Safety monitoring: Aggressive pursuit of remission should never come at the cost of safety oversight. Low-dose ketamine is generally well-tolerated, but longer-term use still warrants periodic monitoring for dissociative symptoms, blood pressure changes, and — with regular use — urinary tract and bladder health. As clinical ambitions for TRD treatment rise, so too should the rigor of follow-up protocols.
Combination approaches: The Psychiatric Times discussion makes clear that no single intervention is likely sufficient for most TRD patients. Ketamine, including low-dose outpatient formats, is most effective when integrated into a broader treatment plan that may include psychotherapy (particularly ketamine-assisted psychotherapy where available), lifestyle medicine, and ongoing psychiatric collaboration. Patients who receive ketamine in isolation, without psychological support structures, may achieve response but fall short of sustained remission.
How Strong Is the Evidence?
It's worth being clear about the evidence base here. The remission-focused clinical philosophy described in Psychiatric Times reflects expert consensus and evolving best practices — it is not a new randomized controlled trial or a specific clinical guideline update. The underlying evidence for ketamine in TRD is reasonably strong for acute response, with multiple RCTs and meta-analyses supporting its efficacy. The evidence for long-term maintenance protocols and full remission specifically is thinner, reflecting the relative novelty of ketamine as a treatment modality and the difficulty of conducting long-duration trials in this population.
For patients and families, the honest framing is this: the clinical community is raising its ambitions for what TRD treatment should achieve, and ketamine is one of the tools increasingly central to those ambitions. The evidence is promising and growing, but protocols are still being refined. Working with a knowledgeable provider who tracks the evolving literature and is willing to individualize your treatment plan remains the most important factor in moving toward genuine remission rather than settling for partial relief.
Share